140 related articles for article (PubMed ID: 21501035)
1. Apolipoprotein A-II: evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis.
Chan DC; Ng TW; Watts GF
Ann Med; 2012 Jun; 44(4):313-24. PubMed ID: 21501035
[TBL] [Abstract][Full Text] [Related]
2. Catabolism of lipoproteins and metabolic syndrome.
Therond P
Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
[TBL] [Abstract][Full Text] [Related]
3. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus.
de Vries R; Borggreve SE; Dullaart RP
Clin Lab; 2003; 49(11-12):601-13. PubMed ID: 14651331
[TBL] [Abstract][Full Text] [Related]
4. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
Kontush A; Chapman MJ
Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
[TBL] [Abstract][Full Text] [Related]
5. [Atherogenic dyslipidaemia in type 2 diabetes].
Zozulińska D
Kardiol Pol; 2006 Oct; 64(10 Suppl 6):S567-71. PubMed ID: 20527378
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein.
Corsetti JP; Bakker SJ; Sparks CE; Dullaart RP
PLoS One; 2012; 7(6):e39110. PubMed ID: 22723940
[TBL] [Abstract][Full Text] [Related]
7. The unique role of apolipoprotein A-I in HDL remodeling and metabolism.
Pownall HJ; Ehnholm C
Curr Opin Lipidol; 2006 Jun; 17(3):209-13. PubMed ID: 16680023
[TBL] [Abstract][Full Text] [Related]
8. Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome.
Volek JS; Fernandez ML; Feinman RD; Phinney SD
Prog Lipid Res; 2008 Sep; 47(5):307-18. PubMed ID: 18396172
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.
Ooi EM; Barrett PH; Chan DC; Watts GF
Clin Sci (Lond); 2008 May; 114(10):611-24. PubMed ID: 18399797
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease.
Smith AG; Muscat GE
Int J Biochem Cell Biol; 2005 Oct; 37(10):2047-63. PubMed ID: 15922648
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome.
Sniderman AD; Faraj M
Curr Opin Lipidol; 2007 Dec; 18(6):633-7. PubMed ID: 17993808
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin is an important determinant of apoA-I catabolism.
Vergès B; Petit JM; Duvillard L; Dautin G; Florentin E; Galland F; Gambert P
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1364-9. PubMed ID: 16574896
[TBL] [Abstract][Full Text] [Related]
13. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
14. A Caucasian male with very low blood cholesterol and low apoA-II without evidence of atherosclerosis.
Park SH; Kim JR; Park JE; Cho KH
Eur J Clin Invest; 2007 Apr; 37(4):249-56. PubMed ID: 17373959
[TBL] [Abstract][Full Text] [Related]
15. Recombinant high-density lipoprotein formulations.
Vucic E; Rosenson RS
Curr Atheroscler Rep; 2011 Feb; 13(1):81-7. PubMed ID: 21057986
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Chapman MJ
Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo.
Watts GF; Ooi EM; Chan DC
Pharmacol Ther; 2009 Sep; 123(3):281-91. PubMed ID: 19490928
[TBL] [Abstract][Full Text] [Related]
18. Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ
Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
[TBL] [Abstract][Full Text] [Related]
19. Increased cholesteryl ester transfer protein activity in impaired glucose tolerance: relationship to high density lipoprotein metabolism.
Pietzsch J; Fuecker K
Croat Med J; 2003 Apr; 44(2):171-7. PubMed ID: 12698508
[TBL] [Abstract][Full Text] [Related]
20. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
Santos-Gallego CG; Ibanez B; Badimon JJ
Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
